Related references
Note: Only part of the references are listed.2010 Update of the international ASAS recommendations for the use of anti-TNF agents in patients with axial spondyloarthritis
Desiree van der Heijde et al.
ANNALS OF THE RHEUMATIC DISEASES (2011)
Treatment benefit or survival of the fittest: what drives the time-dependent decrease in serious infection rates under TNF inhibition and what does this imply for the individual patient?
A. Strangfeld et al.
ANNALS OF THE RHEUMATIC DISEASES (2011)
2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis
J. Braun et al.
ANNALS OF THE RHEUMATIC DISEASES (2011)
ASDAS, a highly discriminatory ASAS-endorsed disease activity score in patients with ankylosing spondylitis
D. van der Heijde et al.
ANNALS OF THE RHEUMATIC DISEASES (2009)
The Assessment of SpondyloArthritis international Society (ASAS) handbook: a guide to assess spondyloarthritis
J. Sieper et al.
ANNALS OF THE RHEUMATIC DISEASES (2009)
No efficacy of subcutaneous methotrexate in active ankylosing spondylitis: a 16-week open-label trial
H. Haibel et al.
ANNALS OF THE RHEUMATIC DISEASES (2007)
Efficacy and safety of adalimumab in patients with ankylosing spondylitis - Results of a multicenter, randomized, double-blind, placebo-controlled trial
Desiree van der Heijde et al.
ARTHRITIS AND RHEUMATISM (2006)
Six months open label trial of leflunomide in active ankylosing spondylitis
H Haibel et al.
ANNALS OF THE RHEUMATIC DISEASES (2005)
Recombinant human tumor necrosis factor receptor, (etanercept) for treating ankylosing spondylitis - A randomized, controlled trial
JC Davis et al.
ARTHRITIS AND RHEUMATISM (2003)
Treatment of active ankylosing spondylitis with infliximab:: a randomised controlled multicentre trial
J Braun et al.
LANCET (2002)
Share Paper
